Company
Headquarters: Shanghai, China
Employees: 12,946
CN¥14.52 Billion
CNY as of July 1, 2025
US$2.03 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Shanghai Shyndec Pharmaceutical Co., Ltd. manufactures drug preparation products in China and internationally. It focuses on anti-infection, cardiovascular and cerebrovascular, anti-tumor, metabolism, and endocrine areas. The company was founded in 1996 and is based in Shanghai, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥10.42 B |
| EBITDA | CN¥1.93 B |
| Gross Profit TTM | CN¥3.81 B |
| Profit Margin | 10.69% |
| Operating Margin | 18.72% |
| Quarterly Revenue Growth | -16.50% |
Shanghai Shyndec Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600420 wb_incandescent